Empirical Finance’s Emergent Biosolutions EBS Stock Holding History

Empirical Finance’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,545	Closed	-$310K	–	475
2022 Q1	$310K	Hold	7,545	–	–	0.03%	406
2021 Q4	$328K	Sell	7,545 -6,538	-46%	-$296K	0.04%	391
2021 Q3	$705K	Hold	14,083	–	–	0.11%	195
2021 Q2	$887K	Buy	+14,083	New	+$905K	0.14%	163
2017 Q1	–	Sell	-264	Closed	-$9K	–	229
2016 Q4	$9K	Buy	+264	New	+$7.92K	0.01%	392

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Empirical Finance's EBS Position: Q2 2022 in Review

Empirical Finance sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 7,545 shares — an estimated $310K sold.

Empirical Finance first reported a position in EBS in Q4 2016 and held it in 5 quarters. The position peaked at $887K in Q2 2021. 232 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

Empirical Finance reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
Empirical Finance sold 7,545 Emergent Biosolutions shares in Q2 2022, an estimated $310K.
Empirical Finance first reported a position in Emergent Biosolutions in Q4 2016 and held it in 5 quarters.
Empirical Finance's Emergent Biosolutions position peaked at $887K in Q2 2021.
232 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Empirical Finance's 13F filing for Q2 2022, filed 1 Aug 2022.